Different biology, different timeline, different metrics
Secondly, reports from FAERS lack medical confirmation, potentially introducing reporter bias (Nomura et al., 2015)
Semaglutide tends to be a good fit for patients interested in established GLP-1 therapy
Report any signs of kidney stress (foamy urine, swelling) or severe digestive upset to your doctor right away
GLP-1 medicines may increase hypoglycemia risk when combined with insulin or sulfonylureas and may delay stomach emptying, affecting absorption of some oral medicines
Its a different medication than tirzepatide (GLP-1 only vs dual GIP/GLP-1 activity), and it is not FDA-approved as of the latest update in our review: Orforglipron: The New Oral GLP-1 Drug Explained